Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | RAMP3 | O60896 | 10/20 | 0.42 |
| ▸ | CALCR | P30988 | 10/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542974 | 0.90 | PTPN1 (0.46) | KEAP1PTPN1RAMP3CALCR | |
| SCHEMBL29904042 | 0.89 | APLNR (0.42) | PTPN1 | |
| SCHEMBL29641613 | 0.89 | KEAP1 (0.51) | KEAP1PTPN1RAMP3CALCRCALCRL | |
| SCHEMBL29904041 | 0.84 | APLNR (0.41) | KEAP1PTPN1 | |
| SCHEMBL30542989 | 0.83 | KEAP1 (0.45) | KEAP1PTPN1CALCRL | |
| SCHEMBL29827555 | 0.83 | KEAP1 (0.52) | KEAP1PTPN1RAMP3CALCR | |
| SCHEMBL29827592 | 0.82 | RAMP3 (0.53) | KEAP1PTPN1RAMP3CALCR | |
| SCHEMBL30493464 | 0.82 | APLNR (0.42) | PTPN1RAMP3CALCR | |
| SCHEMBL30099663 | 0.82 | NAA50 (0.45) | PTPN1RAMP3CALCRSTAT3 | |
| SCHEMBL8643257 | 0.82 | KEAP1 (0.47) | KEAP1RAMP3CALCRCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409709-A1 | LABYRINTHIN-BASED PEPTIDES FOR CANCER IMMUNOTHERAPIES AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS USA LTD (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220089719-A1 | CONSTRUCTS TARGETING LABYRINTHIN OR A PORTION THEREOF AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS (USA) LIMITED (US) | 2022-03-24 | — | — | US | disclosed |